MedTrace Logo

Expanded Access Protocol of 68Ga PSMA 11 PET Imaging of Prostate Cancer

NCT04452136 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2022-03-14

No results posted yet for this study

Summary

This study provides expanded access to radiotracer Gallium 68 (68Ga)-prostate-specific membrane antigen (PSMA)-HBED-CC (68Ga-PSMA-11) with Positron Emission Tomography (PET) imaging for participants with intermediate and high risk prostate cancer before prostatectomy or for suspected biochemical recurrence of their prostate cancer. Compared to conventional imaging, 68Ga PSMA-HBED-CC might improve the ability to localize the sites of recurrent or metastatic disease, which helps with surgical and other treatment planning.

Conditions

  • Prostatic Neoplasms
  • Prostatic Diseases
  • Prostate Cancer
  • Prostate Cancer Metastatic
  • Prostate Cancer Recurrent

Interventions

DRUG

68GA PSMA-HBED-CC

Given IV

Sponsors & Collaborators

  • OHSU Center of Radiochemistry Research

    collaborator UNKNOWN

  • Oregon Health and Science University

    collaborator OTHER

  • OHSU Knight Cancer Institute

    collaborator OTHER

  • Jeanne Link

    lead OTHER

Principal Investigators

  • Nadine Mallak, M.D. · OHSU Knight Cancer Institute

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04452136 on ClinicalTrials.gov